Q1 FY2023 Financial Results February 1, 2023 Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "intend," "plan," "continue," "sustain," "sy ...

收入情况 - U.S. Healthcare Solutions部门的收入从去年同期增长了64亿美元，增长率为6.1%[39] - 国际医疗解决方案部门的收入从去年同期下降了3850万美元，降幅为0.6%[39] 毛利润情况 - U.S. Healthcare Solutions部门的毛利润从去年同期增加了1.076亿美元，增长率为8.4%[41] 费用情况 - 公司在2022年12月31日的总运营费用较去年同期增加了9690万美元，增长率为6.8%[42] 运营收入情况 - 美国医疗解决方案的运营收入在2022年12月31日的三个月内增长了0.6%，达到了572,416,000美元[44] - 国际医疗解决方案的运营收入在2022年12月31日的三个月内下降了10.4%，达到了161,282,000美元[44] 财务情况 - 利息支出净额在2022年12月31日的三个月内减少了13.8%，达到了46,016,000美元[45] - 我们的有效税率在2022年12月31日的三个月内为19.8%，低于2019年同期的24.6%[47] - 我们的现金及现金等价物在2022年12月31日为830.6亿美元，较之前的688.4亿美元有所增加[48] 投资和债务情况 - 我们预计在2023财年将投资约5亿美元用于资本支出，主要包括技术项目的投资[53] - 我们的固定利率债务总额为4,947,755,000美元，可变利率债务总额为696,549,000美元[54] 股票回购和股息情况 - 公司在2022年12月31日拥有10亿美元的股票回购授权，截至当日已回购7.788亿美元的普通股[55] - 公司董事会于2022年11月将每股普通股的季度股息提高了5%，从0.46美元提高到0.485美元[55] 其他财务信息 - 公司与其他两家全国性制药经销商达成了分销商和解协议，根据协议，公司将在未来18年内支付高达64亿美元[55] - 公司在2022年12月31日的现金及现金等价物为16.922亿美元，变动利率债务为6.965亿美元[56]

J.P. Morgan Healthcare Conference JANUARY 2023 Steve Collis Chairman, President & CEO Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "in ...